You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 14, 2025

Details for Patent: 12,064,434


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,064,434
Title:Ribociclib tablet
Abstract:The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an advanced moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
Inventor(s):Rui Costa, Arnaud Grandeury, Bindhumadhavan GURURAJAN
Assignee:Novartis Pharmaceuticals Corp
Application Number:US17/805,956
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 12,064,434

Introduction

When analyzing the scope and claims of a patent, such as United States Patent 12,064,434, it is crucial to delve into several key aspects, including the patent's claims, the patent landscape, and the legal framework governing patent eligibility. Here’s a detailed analysis to help navigate these complexities.

Patent Claims and Scope

Importance of Claim Scope

The scope of a patent claim is pivotal in determining the extent of protection it offers. A common misconception is that broader claims are always better, but this is not the case. Broader claims can be more difficult to get granted and are easier to invalidate due to the abstract idea exception and failure to meet the written description requirement[5].

Claim 12,064,434 Specifics

To analyze the claims of US Patent 12,064,434, one must review the patent specification and claims. Here are some general points to consider:

  • Claim Language: The language used in the claims should be precise and anchored to the embodiments disclosed in the specification. Overly broad claims that invoke generic processes or machinery without specifying a means or method that improves the relevant technology can be at risk of being invalidated under the abstract idea exception[5].

  • Practical Applications: The claims should integrate judicial exceptions into practical applications. For example, if the patent involves AI-related inventions, the claims must show how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field. This is a key takeaway from the 2024 USPTO guidance update on AI patents[1].

  • Written Description Requirement: The claims must be supported by a sufficient written description in the patent specification. This ensures that the claims are not overly broad and are adequately described to meet the statutory requirements[5].

Patent Landscape

Tracking Patents and Claims

Understanding the patent landscape involves identifying which patents and claims are actively protecting the intellectual property and where gaps or opportunities exist. Tools like patent analytics and claim coverage matrices can be invaluable in this process. These tools help categorize patents by claims and scope concepts, making it easier to filter, search, and analyze large numbers of patent claims[3].

Claim Coverage Matrix

A claim coverage matrix can show which patents and claims are actively protecting the intellectual property related to US Patent 12,064,434. This matrix helps identify gaps in current coverage and highlights future design opportunities. It also categorizes the scope concepts of the patent claims into high, medium, or low value, indicating their current and potential future importance to the company[3].

Legal Framework and Recent Updates

USPTO Guidance Update

The 2024 USPTO guidance update on AI patents provides significant insights into evaluating the patent eligibility of AI-related inventions. This update emphasizes the importance of assessing whether a claim integrates a judicial exception into a practical application. It also clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility, provided there is significant human contribution[1].

Abstract Idea Exception

The abstract idea exception, as outlined in the Supreme Court's Alice decision, is a critical consideration. Claims that are directed to a result or effect that is itself an abstract idea, and merely invoke generic processes and machinery, are at risk of being invalidated. This exception is designed to prevent patents from preempting abstract ideas and granting monopolies over them[5].

Recent Court Decisions

Recent court decisions, such as Yu v. Apple Inc. and Minerva Surgical, Inc. v. Hologic, Inc., provide additional guidance on proper claim scope. These decisions highlight the risks of overly broad claims and the importance of ensuring that claims are anchored to the embodiments disclosed in the specification and provide specific means or methods that improve the relevant technology[5].

Practical Applications and Technological Improvements

Real-World Applications

To ensure patent eligibility, the claims of US Patent 12,064,434 must demonstrate real-world applications that provide concrete benefits or solve specific problems. For instance, if the patent involves AI technology, specifying the use of AI in a real-time application, such as enhancing the accuracy of voice commands in hands-free environments, can make the claim patent-eligible by adding a practical application that results in tangible benefits[1].

Technological Improvements

The claims should show how the invention offers a concrete technological improvement. This involves specifying additional elements in the claim that impose meaningful limits on the judicial exception, transforming the claim into patent-eligible subject matter. For example, if the claim involves routine data processing, it must go beyond mere data processing by specifying a practical application that provides a tangible outcome[1].

Key Takeaways

  • Precise Claim Language: Ensure claims are precise and anchored to the embodiments disclosed in the specification.
  • Practical Applications: Claims must integrate judicial exceptions into practical applications to demonstrate concrete benefits.
  • Written Description Requirement: Claims must be supported by a sufficient written description in the patent specification.
  • Patent Landscape Analysis: Use tools like patent analytics and claim coverage matrices to understand the patent landscape.
  • Legal Framework Compliance: Ensure compliance with recent updates and court decisions regarding patent eligibility.

FAQs

  1. What is the importance of claim scope in a US patent application?

    • The claim scope is crucial as it determines the extent of protection offered by the patent. While broader claims may seem desirable, they can be more difficult to get granted and easier to invalidate.
  2. How does the 2024 USPTO guidance update impact AI-related patents?

    • The update refines the process for determining patent eligibility of AI-related inventions by emphasizing the integration of judicial exceptions into practical applications and clarifying that AI-assisted inventions are evaluated on equal footing with other technologies.
  3. What is the abstract idea exception in patent law?

    • The abstract idea exception prevents patents from preempting abstract ideas by ensuring that claims do not merely invoke generic processes and machinery without specifying a means or method that improves the relevant technology.
  4. Why is it important to demonstrate real-world applications in patent claims?

    • Demonstrating real-world applications helps to ensure that the claims provide concrete benefits or solve specific problems, which is essential for patent eligibility.
  5. How can patent analytics help in managing patent claims?

    • Patent analytics tools help in categorizing patents by claims and scope concepts, making it easier to identify gaps in current coverage, highlight future design opportunities, and determine the value of patent claims.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz[1]
  2. ALLERGAN USA, INC. v. MSN LABORATORIES PRIVATE LTD. - CAFC[2]
  3. Patent Analytics - Schwegman[3]
  4. US Patent 12064434 - PharmaCompass[4]
  5. The Importance of Getting the Claim Scope Right in a US Patent Application - Rimon Law[5]

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 12,064,434

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Novartis KISQALI ribociclib succinate TABLET;ORAL 209092-001 Mar 13, 2017 RX Yes Yes 12,064,434 ⤷  Try for Free Y ⤷  Try for Free
Novartis KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate TABLET;ORAL 209935-001 May 4, 2017 RX Yes Yes 12,064,434 ⤷  Try for Free Y ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 2 of 2 entries

International Family Members for US Patent 12,064,434

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Argentina 104257 ⤷  Try for Free
Australia 2016248017 ⤷  Try for Free
Australia 2019201929 ⤷  Try for Free
Australia 2020250190 ⤷  Try for Free
Australia 2022215155 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.